Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent ...

Marcel Imwinkelried, Chief Executive Officer Siegfried: “Aligned with Siegfried's strategy EVOLVE+, the new lab facility marks a key milestone in DINAMIQS' journey to becoming the leading CDMO in the ...

Since its inception, 10 Institut Pasteur scientists have been awarded the Nobel Prize for Medicine, including two in 2008 for ... diseases in antimicrobial resistance, respiratory and vector-borne ...

UD insect ecology and conservation student Thor Freeman pursues medical entomology career with the U.S. Air Force ...

Hope Center for Neurological Disorders, Washington University School of Medicine, St. Louis, USA ...

A 36-year-old man from Jorabagan died from dengue virus at RG Kar Medical College Hospital, marking the first dengue death in ...

RJVA-002 is a locally administered AAV9 viral vector that expresses human GIP and GLP-1 hormones ... results from the Company ...

As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...

Steve Favaloro, Chairman and CEO, said, "I am thrilled to welcome Pam and Stuart to our board at an exciting time in Genezen's development. They bring a wealth of manufacturing, drug development, and ...

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, ...

Researchers say climate change has the potential to increase mosquito numbers and the transmissibility of mosquito-borne ...

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...